Abstract 250P
Background
Treatment for cervical cancer can significantly affect a patient’s quality of life. The purpose of this research: to study the quality of life in patients with cervical cancer and to analyze the dependence of the quality of life indicators on radiation doses obtained when living in areas adjacent to the Semipalatinsk test site.
Methods
In this study, a survey was conducted of 20 patients (women aged 27 to 70 years, average age 52 years) who received chemoradiation therapy. The questionnaire to assess the quality of life, carried out after treatment, using the official versions of questionnaires EORTC QLQ-CX24. The QLQ-CX24 module includes functional and symptomatic scales. The assessment of individual radiation doses received while living in areas exposed to radioactive exposure was carried out in accordance with official guidelines.
Results
The results obtained for functional scales: overall quality of life 78.4 ± 15.2, body image 80.2 ± 15.3, sexual activity 20.4 ± 19.5, sexual satisfaction 52.4 ± 18.3, sexual/vaginal functioning 42.6 ± 19.8 points. For symptomatic scales: symptoms 15.6 ± 12.8, lymphadenoma 12.9 ± 15.4, peripheral neuropathy 23.9 ± 14.7, menopausal symptoms 33.3 ± 28.4, sexual anxiety 32.4 ± 22.5 points.
Individual radiation doses received by patients while living in radioactively contaminated territories range from 1.06 to 36.11 cSv. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established. It is impossible to unequivocally affirm the absence of this dependence due to the insufficient number and heterogeneity of the studied group in a number of parameters.
Conclusions
A sufficiently high scale value indicates the overall quality of life reflects a good level of functioning. The rather low levels of the scales of symptoms, lymphedema, peripheral neuropathy indicate the severity of this symptomatology during preventive exposure to PALS. For the study group, the relationship between indicators of quality of life and individual radiation doses have not been established.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session